ipilimumab
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
Merck’s Keytruda trial stopped early after beating BMS’ Yervoy on survival
March 25, 2015Research and Development, Sales and Marketing BMS, Merck, Yervoy, ipilimumab, keytruda, pembrolizumab
A trial comparing two potential blockbuster cancer treatments has been stopped early, after Merck’s Keytruda beat BMS’ Yervoy in a …
BMS launches skin cancer treatment Yervoy in UK
August 22, 2011Sales and Marketing Yervoy, cancer vaccine, ipilimumab, skin cancer
Bristol-Myers Squibb’s skin cancer treatment Yervoy has been launched in the UK for patients with the deadliest form of the …
European approval for BMS skin cancer vaccine
July 14, 2011Sales and Marketing BMS, Yervoy, ipilimumab
Bristol-Myers Squibb’s skin cancer vaccine Yervoy has been approved in Europe after showing survival benefits in one of the most …
BMS skin cancer vaccine hits phase III target
March 23, 2011Research and Development BMS, Bristol-Myers Squibb, advanced inoperable skin cancer, advanced melanoma, cancer drugs, cancer vaccine, ipilimumab
Bristol Myers Squibb’s cancer vaccine ipilimumab has increased overall survival in advanced melanoma patients. The therapy was being tested as …
BMS skin cancer drug hits US regulatory delay
November 3, 2010Research and Development BMS, Bristol-Myers Squibb, FDA, MDX010-020 trial, ipilimumab, skin cancer
US regulators have announced they need more time to assess Bristol-Myers Squibb’s skin cancer treatment ipilimumab. The FDA will not …
BMS’ melanoma drug given priority review
August 19, 2010Sales and Marketing BMS, ipilimumab
Bristol-Myers Squibb’s promising new treatment for skin cancer melanoma has been given a priority review by the FDA. The company …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
